{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:23:50Z","timestamp":1760189030296,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":4847,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.exphem.2008.11.005","type":"journal-article","created":{"date-parts":[[2009,1,10]],"date-time":"2009-01-10T05:54:30Z","timestamp":1231566870000},"page":"395-401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells"],"prefix":"10.1016","volume":"37","author":[{"given":"Ashley","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Alhashimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Myssina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather G.","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa L.","family":"Holyoake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2008.11.005_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2008.11.005_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2008.11.005_bib3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukaemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.exphem.2008.11.005_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2008.11.005_bib5","doi-asserted-by":"crossref","first-page":"22925","DOI":"10.1016\/S0021-9258(17)31596-X","article-title":"Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia","volume":"269","author":"Oda","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2008.11.005_bib6","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198306233082502","article-title":"Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome positive chronic myelogenous leukemia","volume":"308","author":"Coulombel","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2008.11.005_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/beha.1999.0017","article-title":"Normal and leukaemic haematopoiesis in bone marrow and peripheral blood of patients with chronic myeloid leukaemia","volume":"12","author":"Frassoni","year":"1999","journal-title":"Baillieres Best Pract Res Clin Haematol"},{"key":"10.1016\/j.exphem.2008.11.005_bib8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2008.11.005_bib9","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2008.11.005_bib10","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/sj.leu.2404189","article-title":"BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry","volume":"20","author":"Hamilton","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2008.11.005_bib11","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.005_bib12","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.exphem.2008.11.005_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2008.11.005_bib14","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2008.11.005_bib15","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","article-title":"In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML","volume":"106","author":"White","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.005_bib16","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1126\/science.293.5538.2163a","article-title":"Roots of clinical resistance to STI-571 cancer therapy","volume":"293","author":"Hochhaus","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.exphem.2008.11.005_bib17","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.005_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.005_bib19","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2008.11.005_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.005_bib21","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"J\u00f8rgensen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.005_bib22","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2405086","article-title":"Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors","volume":"22","author":"Konig","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2008.11.005_bib23","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","article-title":"Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by\u00a0the dual Src\/Abl kinase inhibitor SKI-606","volume":"111","author":"Konig","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.005_bib24","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1182\/blood-2005-01-0210","article-title":"Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment","volume":"105","author":"Schultheis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.005_bib25","first-page":"1731","article-title":"Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients","volume":"47","author":"Maxwell","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2008.11.005_bib26","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2006-10-050799","article-title":"Conventional Western blotting techniques will not reliably quantify p210BCR-ABL1 levels in CML mononuclear cells","volume":"109","author":"Patel","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.005_bib27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/gcc.20377","article-title":"Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2","volume":"45","author":"Patel","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.exphem.2008.11.005_bib28","first-page":"353","article-title":"Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition","volume":"15","author":"Singer","year":"2006","journal-title":"Oncol Rep"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X08005237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X08005237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:27:04Z","timestamp":1759566424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X08005237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0301472X08005237"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2008.11.005","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2008.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}